Issue 117

Tryp

Psilocybin reduces binge eating episodes by 80%

Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder, with daily binge eating episodes reduced by an average of 80%.

To discuss the study and the company’s drug development programmes, PSYCH spoke with Tryp’s CEO and Chief Scientific Officer Jim Gilligan.

‘We teed up several clinical studies with oral psilocybin while we’re developing TRP-8803, our proprietary product which is an IV infusion of psilocin,’ explained Gilligan.

‘These studies are in eating disorders and nociplastic pain, to confirm that we will see a clinical benefit that we can accelerate.’

READ MORE

DATA ON DMT-ASSISTED THERAPY FOR MAJOR DEPRESSIVE DISORDER

Twelve weeks after Small Pharma’s intravenous DMT administration there was a 57% remission rate in patients.

Read More

AUSTRALIA'S LARGEST PSILOCYBIN STUDY CONFIRMED

Approximately 160 patients will take part in the randomised controlled trial of psilocybin-assisted therapy.

Read More

BUSINESS AND INVESTMENT

MINDCURE announces financial results.

Investment trends in psychedelic healthcare.

The development of psychedelic medicines in 2023.

The impact of psychedelic medicine on workplace performance.

MAPS’ MDMA treatment expected to be regulated in 2024.

The different paradigms of ketamine treatment.

COMPASS Pathways’ mental health ecosystem.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Early Bird tickets on sale for £299 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

The mechanism of action of non-hallucinogenic 5-HT2A agonists.

Urge for research into psychedelic therapy to treat loneliness.

Psycheceutical Bioscience files patent for topical ketamine treatment.

Psychotherapeutic and neurobiological processes associated with ayahuasca.

The market for MDMA-assisted therapy could be worth over US$1 billion by 2026.

The Psychedelics as Medicine Report: Fourth Edition provides industry intelligence, empowering investors to make informed decisions.

COMPLIMENTARY DOWNLOAD

REGULATION AND LEGISLATION

Virginia senators approve psilocybin rescheduling bill.

Missouri Republican pushes for psilocybin decriminalisation.

New York’s bill to decriminalise drug possession.

Psilocybin legalisation in the state of Washington.

Oregon’s legal psilocybin framework begins.

An overview of the Breakthrough Therapies Act.

Drug scheduling limits access to essential medicines.

Police in British Columbia prepare for drug decriminalisation.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to engage with an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

The ban on the sale and possession of nitrous oxide.

The development of less toxic alternatives to alcohol.

Mental health chatbot earns UKCA medical device certification.

Birdsong boosts mental wellbeing for 90% of people.

Do you know a spokesperson who could provide insights on the future of psychedelic healthcare?

Previous symposium speakers include:

  • Rick Doblin – Founder, MAPS
  • Cosmo Feilding Mellen – CEO, Beckley Psytech
  • Carol Routledge – Chief Medical and Scientific Officer, Small Pharma
  • MP Crispin Blunt – Chair, The Conservative Drug Policy Reform Group
SPEAKING OPPORTUNITIES
Partner with us